A life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Genomic Health is a good company with growing revenue that got taken down too far after reporting earnings in line with expectation. Their tests for breast cancer have continued to see strong growth in sales. They are ramping up research and their sales force and overhead is making it appear that they are not growing. They have several more tests in clinical trials that are also promising. All are less invasive than existing tests. SInce it has been through the FDA once then things should do better on the next series for prostrate cancer, melanoma, colon cancer, etc. Overall, this little genome company has shown that it has the ability to grow in this field. Decent revenue to fund future testing.